- Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial
Nature Medicine · 2026
- The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials
Diabetes Research and Clinical Practice · 2026
- Cardiovascular Outcomes of Semaglutide in Adults With Congenital Heart Disease
The American Journal of Cardiology · 2026
- Generic GLP-1 receptor agonists in India: an opportunity to close the cardiovascular evidence gap
The Lancet Regional Health - Southeast Asia · 2026
- Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use
Cardiology · 2026
- Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.
2026
- Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel
Internal Medicine Journal · 2026
- Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes.
2026
- Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives
Journal of Personalized Medicine · 2026
- Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients
Frontiers in Cardiovascular Medicine · 2026
- Combined Semaglutide and Sodium–Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis
Diabetes Therapy · 2026
- Cardiovascular and kidney outcomes of semaglutide and the annual eGFR slope in adults with and without type 2 diabetes: data extraction sheet, analysis code and search records for a systematic review and meta-analysis of randomised controlled trials
2026
- SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis
Frontiers in Pharmacology · 2026
- BEYOND WEIGHT LOSS: EMERGING EXTRA-METABOLIC APPLICATIONS OF GLP-1 RECEPTOR AGONISTS IN CARDIOVASCULAR, RENAL, NEUROLOGICAL AND INFLAMMATORY DISORDERS: A NARRATIVE REVIEW
International Journal of Innovative Technologies in Social Science · 2026
- Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome
Medical Sciences · 2026
- Histological, Immunohistochemical, and Biochemical Study of the Effect of Semaglutide on the Cardiac Muscle of Obese and Non-Obese Albino Rat: The Role of Adiponectin, Tumor Necrosis Factor Alpha (TNF-α), and Caspase-3
The Egyptian Journal of Histology · 2026
- Effects of semaglutide on subclinical cardiovascular health in people with HIV
AIDS · 2026
- Efficacy and Safety of Semaglutide According to Frailty Status
JAMA Cardiology · 2026
- Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology
Frontiers in Cardiovascular Medicine · 2026
- Obesity-driven Cardiovascular Risk: Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists
Glucolipid metabolic disorders · 2026
- MULTIDIRECTIONAL CLINICAL BENEFITS OF GLP-1 AGONISTS: A REVIEW OF EFFICACY IN WEIGHT LOSS AND CARDIOVASCULAR PROTECTION
International Journal of Innovative Technologies in Social Science · 2026
- Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review
Endocrinology Diabetes & Metabolism · 2026
- The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis
Nutrition Metabolism and Cardiovascular Diseases · 2026
- Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial
Journal of Diabetes and its Complications · 2026
- Dapagliflozin Alone or Combined with Semaglutide
Journal of the ASEAN Federation of Endocrine Societies · 2026
- Semaglutide‐Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta‐Analysis
The Journal of Clinical Pharmacology · 2026
- GLP1 receptor agonism attenuates anthracycline and HER2 targeted therapy induced cardiac dysfunction and systemic inflammation in non-diabetic models
European Heart Journal Supplements · 2026
- Not Just for Diabetes: The Next Frontier for GLP-1 Agonists
The Journal of the American Board of Family Medicine · 2026
- Retrospective audit of the current anaesthetic peri–operative approach to patients prescribed semaglutide
Perioperative Care and Operating Room Management · 2026
- Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists
Cardiovascular Toxicology · 2026
- Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study
Frontiers in Endocrinology · 2026
- Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
European Heart Journal · 2026
- Long-term effects of weight-reducing drugs in people with hypertension
Cochrane Database of Systematic Reviews · 2026
- 1291-OR: Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial
Diabetes · 2026
- Clinical Effectiveness and Safety of Oral Semaglutide in a Real-World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score-Matched Analysis
Pharmaceuticals · 2026
- 2580-P: Multimodal Imaging Reveals Organ- and Depot-Specific Adipose Tissue and Lean Mass Changes upon Weight-Loss Pharmacotherapy in NHPs
Diabetes · 2026
- In T2D inadequately controlled with metformin, orforglipron reduced HbA <sub>1c</sub> more than oral semaglutide at 52 wk
Annals of Internal Medicine · 2026
- 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study
The Lancet Diabetes & Endocrinology · 2026
- Association between Semaglutide 2.4 mg and Risk of Cardiovascular Events in Patients with Heart Failure in the Real-world: Results from the SCORE-HF Study
Journal of Cardiac Failure - Intersections · 2026
- Highlighting the latest research: May 2026
British Journal of Cardiac Nursing · 2026
- Comparative 12-month cardiometabolic impact of semaglutide vs tirzepatide: a synthetic propensity-matched analysis
Cardiovascular Research · 2026
- Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review
Therapeutic Advances in Drug Safety · 2026
- B52-20 A Broken Heart: Ozempic-Induced Takotsubo Cardiomyopathy
American Journal of Respiratory and Critical Care Medicine · 2026
- Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study
Diabetes and Vascular Disease Research · 2026
- THE GLP–1 RECEPTOR AGONIST SEMAGLUTIDE PRESERVES CARDIAC FUNCTION, REDUCES INFLAMMATION–DRIVEN CARDIOTOXICITY WITH CARDIO–RENAL BENEFITS IN NON–DIABETIC MODELS EXPOSED TO ANTHRACYCLINES AND HER2 BLOCKADE
European Heart Journal Supplements · 2026
- COMPARATIVE 12–MONTH CARDIOMETABOLIC: IMPACT OF SEMAGLUTIDE VS TIRZEPATIDE: A SYNTHETIC PROPENSITY–MATCHED ANALYSIS
European Heart Journal Supplements · 2026
- GLP1–RA SEMAGLUTIDE AND SLOWING PROGRESSION OF AORTIC VALVE STENOSIS IN NON DIABETIC PATIENTS
European Heart Journal Supplements · 2026
- Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5
Journal of Endocrinological Investigation · 2026
- Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data
European Journal of Heart Failure · 2026
- Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly
Diabetes Care · 2026